Form 4: C4 Therapeutics Executive Boyle Exercises Stock Options, Disposes of Shares for Tax Obligations
SEC Form 4 Filing
Scott N. Boyle, Chief Business Officer of C4 Therapeutics, exercised performance restricted stock units and disposed of shares to cover tax obligations on September 16, 2024.
Summary
- On September 16, 2024, Scott N. Boyle, the Chief Business Officer of C4 Therapeutics, exercised 2,250 performance restricted stock units (PRSUs).
- Following the transaction, Boyle directly owns 53,919 shares of C4 Therapeutics common stock.
- 661 shares were disposed of at a price of $6.36 to cover tax withholding obligations related to the vesting and settlement of the PRSUs.
- After the transaction, Boyle directly owns 14,250 derivative securities.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the document simply reports transactions related to stock options and tax obligations, which are routine.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track executive compensation and ownership changes.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding executive compensation and stock ownership.
Key Dates
| Date | Description |
|---|---|
| 09/16/2024 | Date of earliest transaction: Exercise of performance restricted stock units and disposal of shares for tax obligations. |
| 09/17/2024 | Date of signature on the Form 4 filing. |
| 02/28/2025 | Expiration date of the performance restricted stock units. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.